Lalo Flores (Century)
As allogeneic cell therapy approaches flourish, Century loads up $160M to scale iPSC platform for CAR-T, CAR-NK
Lalo Flores is confident he’s found the way forward in cell therapy.
The feeling, to be sure, is not exclusive. Thanks to splashy companies like Allogene and Artiva, biopharma is well aware of the promises of allogeneic therapies as next-generation alternatives to the autologous CAR-Ts that have already made it to the market. But fewer are talking about a finer distinction within that allogeneic group: Where do you find the cells to engineer and turn into a final off-the-shelf product?
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters